In January 2019, Bristol-Myers Squibb and Celgene Corporation announced that they had entered into a definitive merger agreement for BMS to acquire Celgene for $74 billion. In this free webinar we discuss the proposed BMS acquisition of Celgene along with the forces behind and the potential divesture scenarios to see how the technology landscape will be affected;
the effect of M&As on the innovation landscape is becoming more important for policy makers; and lessons from decisions in the Dow/DuPont merger and how these might impact Bristol-Myers Squibb.